Montek (Pertechnetate (99mtc) Sodium)

Technetium-99m Pertechnetate Sodium, the active ingredient in Montek, is a radiopharmaceutical presented as a solution for injection for intravenous and ocular use. It enables functional imaging of the thyroid, gastric mucosa, salivary glands, renal cortex, and ocular tissues.

GNH USA supplies Montek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with consistent quality and regulatory compliance.

Montek is used in diagnostic imaging to assess the function of organs that take up pertechnetate. - Thyroid scintigraphy: visualizes thyroid uptake and function for diagnostic evaluation. - Gastric mucosa imaging: assesses gastric mucosal integrity and emptying. - Renal cortical imaging: evaluates renal cortical perfusion and differential function. - Brain perfusion studies: measures cerebral blood flow for neurological assessment. - Ocular blood flow imaging: examines perfusion of ocular tissues for ophthalmic diagnostics.

Adverse reactions are generally mild and related to the radiopharmaceutical nature of the product.

Common Side Effects: - Nausea: transient mild nausea following injection. - Injection site pain: brief discomfort at the venipuncture site. - Flushing: temporary facial flushing. - Headache: mild headache reported in some patients. - Dizziness: occasional light‑headedness. - Metallic taste: brief metallic sensation in the mouth.

Serious or Rare Side Effects: - Allergic reaction: anaphylaxis or severe hypersensitivity. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced tissue injury: rare localized damage. - Thyroid dysfunction: abnormal thyroid hormone levels. - Renal impairment: rare worsening of renal function.

When using Montek, clinicians should observe specific safety measures. - Patient screening: evaluate thyroid status and pregnancy before administration. - Radiation safety: limit exposure to staff and other patients per local regulations. - Allergy assessment: confirm no known hypersensitivity to technetium compounds. - Concurrent imaging: avoid other radiopharmaceuticals within 24 hours. - Dosimetry compliance: adhere to recommended administered activity guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Montek may interact with substances that affect tracer uptake or radiation exposure.

Major Interactions (Avoid): - Iodine‑containing contrast agents: interfere with pertechnetate uptake. - Thyroid hormone therapy: alters thyroid imaging results. - Radioactive iodine therapy: cumulative radiation risk.

Moderate Interactions (Monitor Closely): - Diuretics: may modify renal cortical imaging. - Anticholinergic drugs: can reduce salivary gland uptake. - Beta‑blockers: may affect heart rate during perfusion studies.